Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle.
B FrigerioS MorlinoE LuisonE SeregniA LorenzoniA SattaR ValdagniA BogniC ChiesaM MiraS CanevariA AlessiAlessandro Massimo GianniPublished in: Journal of experimental & clinical cancer research : CR (2019)
Preclinical in vivo results of our immuno-PET reagent are highly promising. The target to background ratio is improved notably using PET compared to SPECT previously performed. These data suggest that, upon clinical confirmation of sensitivity and specificity, our anti-PSMA 124I-scFvD2B may be superior to other diagnostic modalities for PCa. The possibility to combine in patients our 124I-scFvD2B in multi-modal systems, such as PET/CT, PET/MR and PET/SPECT/CT, will provide quantitative 3D tomographic images improving the knowledge of cancer biology and treatment.
Keyphrases
- pet ct
- positron emission tomography
- prostate cancer
- end stage renal disease
- computed tomography
- ejection fraction
- chronic kidney disease
- magnetic resonance imaging
- stem cells
- contrast enhanced
- high resolution
- squamous cell carcinoma
- prognostic factors
- magnetic resonance
- cell therapy
- optical coherence tomography
- pet imaging
- bone marrow
- big data
- young adults
- dual energy